| Literature DB >> 29793728 |
Divyanshu Dubey1, Shannon R Hinson2, Evan A Jolliffe1, Anastasia Zekeridou1, Eoin P Flanagan1, Sean J Pittock3, Eati Basal2, Daniel A Drubach1, Daniel H Lachance1, Vanda A Lennon4, Andrew McKeon5.
Abstract
In this prospective evaluation of serum and CSF samples, all but two CSF GFAPα-IgG positive patients had autoimmune meningoencephalomyelitis while serum GFAPα-IgG positivity alone was less specific. Phenotypes were diverse among patients that were serum positive only. Adult and pediatric clinical presentations were similar. Most patients were immunotherapy responsive. Co-existing NMDA-R-IgG and cancer were associated with lack of response to first-line immunotherapy. Among patients with follow-up information, 18% had relapses. This study demonstrates CSF GFAPα-IgG is a specific autoimmune meningoencephalomyelitis biomarker, with favorable corticosteroid response. Lack of response should prompt evaluation for co-existing NMDA-R-IgG or malignancy.Entities:
Keywords: Autoimmune; Cerebrospinal fluid; Glial fibrillary astrocytic protein; Meningoencephalomyelitis; Pediatric
Mesh：
Substances：
Year: 2018 PMID： 29793728 DOI： 10.1016/j.jneuroim.2018.04.016
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478